Recruiting Pulmonary Embolism Studies in Orange
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in chil...
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate. The main questions it aims to answer are: * Does AP301 lo...
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on my...
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dediffer...
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer o...
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective is to ...
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage...
An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Approximately 30 patients will take VTX2735. The study consists of a ...
About Pulmonary Embolism Clinical Trials in Orange
Pulmonary embolism (PE) is a blockage of an artery in the lungs, usually caused by blood clots that travel from the deep veins of the legs. It can be life-threatening and requires immediate medical attention. Treatment includes anticoagulants and in severe cases, thrombolytic therapy.
There are currently 8 pulmonary embolism clinical trials recruiting participants in Orange, CALIFORNIA. These studies are seeking a combined 1,684 participants. Research is being sponsored by Nationwide Children's Hospital, Alebund Pharmaceuticals, Dennis M. McNamara, MD, MS and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Pulmonary Embolism Clinical Trials in Orange — FAQ
Are there pulmonary embolism clinical trials in Orange?
Yes, there are 8 pulmonary embolism clinical trials currently recruiting in Orange, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Orange?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Orange research site will contact you about next steps.
Are clinical trials in Orange free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Orange studies also compensate for your time and travel.
What pulmonary embolism treatments are being tested?
The 8 active trials in Orange are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary embolism.
Data updated March 2, 2026 from ClinicalTrials.gov